EMGALITY has distinct US indications for adult migraine prevention and episodic cluster headache. The 120 mg and 100 mg presentations belong to different labeled treatment contexts and should not be treated as interchangeable packs.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | galcanezumab-gnlm |
| Medicine class | CGRP antagonist monoclonal antibody |
| Forms and strengths | Subcutaneous injection: 120 mg/mL single-dose prefilled pen or syringe; 100 mg/mL single-dose prefilled syringe |
Two headache conditions, separate instructions
The US label covers migraine prevention and treatment of episodic cluster headache in adults. These are different diagnoses. The cluster-headache indication does not mean EMGALITY is a general acute migraine medicine, and the two regimens should not be combined or transferred between conditions without prescribing advice.
Source: [1]
Match the presentation to the indication
The source lists 120 mg/mL pens and syringes and a 100 mg/mL syringe. Migraine prevention uses a loading regimen followed by monthly maintenance; episodic cluster headache uses a distinct amount during the cluster period. The prescribed product, number of injections and treatment calendar must be confirmed by the clinical team.
Source: [1]
Use the instructions for the actual device
EMGALITY is injected under the skin. A pen and a syringe require their own instructions, training, storage and preparation checks. Do not infer the administration technique from another biologic injection. Record the presentation and last injection date so that a loading or cluster-period instruction is not mistaken for routine maintenance.
Source: [1]
Serious reactions and constipation
The current label warns about serious hypersensitivity and constipation with serious complications. Allergy can occur days after administration and may be prolonged. Severe allergic symptoms need urgent help; severe constipation or significant abdominal symptoms warrant prompt contact with the treating team. Injection-site reactions are also reported.
Source: [1]
Blood pressure and circulation follow-up
New or worsening hypertension and Raynaud's phenomenon are labeled concerns. Report blood-pressure increases or new painful, cold or discolored fingers or toes. Changes to preventive treatment should be clinician-led, with a separate plan for acute migraine needs rather than a self-directed exchange with another antibody.
Further reading includes the AIMOVIG and EMGALITY comparison. Its selected comparison facts do not provide a switching or dose-conversion plan.
Source: [1]
Questions and answers
Are EMGALITY's 100 mg and 120 mg products interchangeable?
They have different labeled treatment contexts. The indication and prescribed regimen must be checked before selecting a presentation.
Does the cluster-headache indication include all headache disorders?
No. The cited indication is episodic cluster headache in adults, distinct from migraine prevention.
Does EMGALITY now carry a serious-constipation warning?
Yes. The current cited label includes constipation with serious complications as well as hypersensitivity and vascular warnings.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026